Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 147540
Corporate User License Price USD 6000
Corporate User License Price INR 442620
Site License Price USD 4000
Site License Price INR 295080
Request a Quote

Report Title

Neutropenia-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Neutropenia-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Neutropenia-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Neutropenia-Pipeline Review, H1 2017



Executive Summary

Neutropenia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia-Pipeline Review, H1 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 2, 1, 4, 3, 1, 8 and 3 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neutropenia-Overview

Neutropenia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Neutropenia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neutropenia-Companies Involved in Therapeutics Development

Adello Biologics LLC

Apotex Inc

Arven Ilac

BeyondSpring Pharmaceuticals Inc

Cellerant Therapeutics Inc

Cleveland BioLabs Inc

Coherus BioSciences Inc

Dr. Reddy's Laboratories Ltd

Eurofarma Laboratorios SA

Intas Pharmaceuticals Ltd

Ligand Pharmaceuticals Inc

Lupin Ltd

Mycenax Biotech Inc

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Neutropenia-Drug Profiles

ACN-8337-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARVMIC-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBLB-612-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LG-7455-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim (recombinant)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romyelocel-L-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-7-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamibarotene-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neutropenia-Dormant Projects

Neutropenia-Product Development Milestones

Featured News & Press Releases

Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar

Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention

Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo

Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)

Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO

Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case

Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case

Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study

May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication

Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study

Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701

Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program

Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Neutropenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Neutropenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neutropenia-Pipeline by Adello Biologics LLC, H1 2017

Neutropenia-Pipeline by Apotex Inc, H1 2017

Neutropenia-Pipeline by Arven Ilac, H1 2017

Neutropenia-Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017

Neutropenia-Pipeline by Cellerant Therapeutics Inc, H1 2017

Neutropenia-Pipeline by Cleveland BioLabs Inc, H1 2017

Neutropenia-Pipeline by Coherus BioSciences Inc, H1 2017

Neutropenia-Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Neutropenia-Pipeline by Eurofarma Laboratorios SA, H1 2017

Neutropenia-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Neutropenia-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Neutropenia-Pipeline by Lupin Ltd, H1 2017

Neutropenia-Pipeline by Mycenax Biotech Inc, H1 2017

Neutropenia-Pipeline by Prolong Pharmaceuticals LLC, H1 2017

Neutropenia-Pipeline by Richter Gedeon Nyrt, H1 2017

Neutropenia-Pipeline by Sandoz International GmbH, H1 2017

Neutropenia-Pipeline by USV Pvt Ltd, H1 2017

Neutropenia-Dormant Projects, H1 2017

Neutropenia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Adello Biologics LLC, Apotex Inc, Arven Ilac, BeyondSpring Pharmaceuticals Inc, Cellerant Therapeutics Inc, Cleveland BioLabs Inc, Coherus BioSciences Inc, Dr. Reddy's Laboratories Ltd, Eurofarma Laboratorios SA, Intas Pharmaceuticals Ltd, Ligand Pharmaceuticals Inc, Lupin Ltd, Mycenax Biotech Inc, Prolong Pharmaceuticals LLC, Richter Gedeon Nyrt, Sandoz International GmbH, USV Pvt Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand